Clinical Analysis of Combined Plasma Antithrombin Ⅲ,D-dimer,and Fibrinogen Degradation Product Assays in the Diagnosis and Treatment of Patients with Sudden Deafness
Objective:The clinical value of microthrombosis in different types of sudden sensorineural deafness(SSNHL)was investigated by the combined analysis of patients'plasma antithrombin Ⅲ(AT-Ⅲ),D-dimer(D-dimer),and fibrinogen degradation product(FDP).Methods:60 patients with sudden deafness admitted to the hospital from January 2021 to May 2022 were selected as the sudden deafness group,and another 70 patients with normal hearing in nasal septal deviation,vocal polyp,preauricular fistula,and adult snoring who were hospitalized in the same period were selected as the control group.According to the results of pure range,the patients of the sudden deafness group were divided into 12 patients in 100-frequency group,12 patients in high-frequency group,and 30 patients in full-frequency group.The levels of AT-Ⅲ,D-dimer and FDP were compared between the two groups.Results:The levels of D-dimer and FDP in the sudden deafness group were lower than those in the control group,and the levels of AT-Ⅲ were higher than those in the control group,and the differences were statistically significant(t=3.935,5.142,5.158;P＜0.05).The levels of D-dimer and FDP in the high-frequency group and full-frequency group were higher than those in the control group and low-frequency group,and the levels of AT-Ⅲ were lower than those in the control group and low-frequency group,and the difference was statistically significant(F=7.896,14.588,12.839;P＜0.05).Conclusion:The combined test of AT-Ⅲ,D-dimer and FDP is convenient and accurate,which provides a theoretical basis for thrombolytic therapy for different types of patients in the clinic,and then designates an individualized diagnosis and treatment plan for the use of microcirculation-improving and thrombolytic drugs in order to obtain better clinical efficacy.
NETL
NSTL
万方数据
维普
